Glaukos Completes Patient Enrollment in Pivotal Phase of U.S. IDE Clinical Trial for iStent SUPRA®
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced the completion of patient enrollment in the pivotal phase of its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) trial for the iStent SUPRA® Suprachoroidal Micro-Bypass Stent. The iStent SUPRA prospec